CE vs FDA, How to Choose Medical Protective Equipment?

A Comparative Analysis of the World's Two Dominant Medical Device Approval Frameworks

For medical device manufacturers eyeing global markets, two certifications stand above all others: the CE Mark required for entry into the European Union, and FDA 510(k) Clearance / PMA Approval required for the United States. While both systems serve the same fundamental purpose - ensuring device safety and efficacy - their philosophies, processes, and outcomes differ dramatically.

Two surgeons with cross-Atlantic clinical experience - Dr. Dan Z. Reinstein (London Vision Clinic / Columbia University) and Dr. A. John Kanellopoulos (NYU Langone Medical Center) - offered a rare side-by-side assessment in a landmark commentary. Their insights, combined with official regulatory data, reveal a system fundamentally shaped by philosophy: Europe trusts manufacturers and physicians with more autonomy; the United States imposes more centralized control and procedural burden.

The most fundamental difference between the two systems lies in where they place the burden of proof - and trust.

The CE Mark model operates on a principle of manufacturer accountability coupled with regulatory trust. Under EU MDR (Regulation 2017/745), manufacturers may pursue clinical evaluation - a systematic review of existing published evidence for equivalent devices - as an alternative to conducting new clinical trials. This allows manufacturers to leverage the global body of scientific literature rather than starting from scratch. Physicians, in turn, are granted greater latitude to optimize device parameters based on their clinical judgment, rather than being locked into trial-specific settings.

The FDA model, by contrast, places significant emphasis on centralized review. Even the widely-used 510(k) pathway - intended as a "fast track" for moderate-risk devices - requires proof of Substantial Equivalence (SE) to an already-cleared predicate device. This creates a dependency: if no suitable predicate exists, manufacturers must pursue the more burdensome De Novo or Premarket Approval (PMA) pathways, which involve full clinical trials and can take years.

"The CE Mark approval method puts more onus on the manufacturer - and also endues the manufacturer with a greater degree of trust. The company can decide, in its clinical evaluation, whether the existing body of evidence is sufficient to claim safety and efficacy."

- Dr. Dan Z. Reinstein, Cataract & Refractive Surgery Today Europe, February 2015

One of the most consequential differences in practice is timeline.

CE Mark review cycles are typically three times shorter than their FDA counterparts, according to Dr. Reinstein's analysis. For a Class II medical device, EU MDR allows manufacturers to file technical documentation with a Notified Body and receive a CE Mark in weeks to a few months, depending on device complexity and the Notified Body's workload.

FDA 510(k) carries a statutory review period of 90 days, but real-world timelines often stretch to 6-12 months due to multiple rounds of agency questions and requests for supplementary data. PMA submissions - required for high-risk Class III devices - routinely take 1-3 years or longer.

The practical consequence: A manufacturer can update a device profile or introduce a new indication in Europe with minimal additional work, while US users of the same technology remain constrained to the parameters used in the original FDA approval studies.

This is where the two systems diverge most sharply in their demands on manufacturers.

The FDA PMA pathway requires comprehensive clinical trial data demonstrating safety and effectiveness - often including randomized controlled trials (RCTs). Even the 510(k) pathway, while less demanding, requires substantial non-clinical bench testing, and FDA has increasingly scrutinized whether submitted data truly supports substantial equivalence.

According to FDA's own classification data: Class I devices (lowest risk) represent ~35% of all medical devices; 93% are exempt from 510(k) requirements.

Class II devices represent ~53% of all devices; most require 510(k) clearance. Class III devices (~9%) represent the highest risk and generally require PMA approval.

EU MDR, which fully took effect on May 26, 2021, replaced the older Medical Device Directives (MDD) with more stringent requirements - but still retains the clinical evaluation pathway. Manufacturers must submit a Clinical Evaluation Report (CER) demonstrating adequate clinical data, compliance with relevant GSPR (General Safety and Performance Requirements), and a post-market clinical follow-up (PMCF) plan. For Class III and implantable devices, clinical investigations are typically required. For lower-risk categories, a well-structured CER referencing existing evidence may suffice.

Both systems have strengthened their post-market oversight in recent years, but EU MDR imposes notably more rigorous continuous obligations.

• Post-Market Clinical Follow-Up (PMCF): Ongoing collection of clinical data after CE Mark is granted
• Periodic Safety Update Reports (PSUR): Mandatory for Class IIa and above
• EUDAMED Database: Full registration of devices, actors, and incidents
• Unique Device Identification (UDI): Mandatory, linked to EUDAMED

• Medical Device Reporting (MDR): Mandatory reporting of adverse events
• Post-Market Surveillance: 21 CFR Part 806 - corrections and removals reporting
• UDI System: Implemented per FDA's UDI Rule (21 CFR Part 830)
• QSR (Quality System Regulation): 21 CFR Part 820 mandates ongoing quality system compliance

Despite the differences, Dr. Reinstein notes: "There are no more product recalls in Europe than in the United States, and there are stringent quality management systems that continue to monitor results after the CE Mark has been granted."

Perhaps the most strategically significant practical difference is geographic scope:

• CE Mark is recognized across all 27 EU member states plus EEA countries (Norway, Iceland, Liechtenstein), and many countries outside Europe - including parts of Asia, Latin America, and the Middle East - accept or reference CE Mark as a benchmark.
• FDA 510(k) / PMA is valid only in the United States. Manufacturers seeking global access must pursue separate approvals in each jurisdiction.

This asymmetry is a major factor in manufacturers' strategy: for most companies, securing a CE Mark first is more commercially efficient, then supplementing with FDA clearance for the US market.

The FDA 510(k) process, while less expensive than a full PMA, still imposes significant indirect costs: internal resources for documentation, external consulting, and extended opportunity cost from delayed market entry.

Dr. Reinstein illustrated the practical consequences of this regulatory divergence with a striking example from ophthalmology:

"Solutions for repair of refractive surgery complications - such as topography-guided custom ablation - have been helping patients with decentered ablations and small optical zones and night vision problems in Europe and Asia since 1998, whereas many unhappy patients in the United States are still denied this kind of help by the over-strict, expensive FDA approval process."

This example underscores a broader point: the FDA's more conservative approach can delay clinically meaningful innovations from reaching patients - even when robust scientific evidence already exists in the published literature.

There is no single right answer - the answer depends on the lens you apply:

Both Dr. Reinstein and Dr. Kanellopoulos - despite having deep experience with both systems - came to a nuanced conclusion: the CE Mark system, while less prescriptive in its approval pathway, is not less safe. Stringent post-market surveillance, Notified Body audits, and EUDAMED registration create a robust accountability framework that, in practice, produces comparable safety outcomes without the bureaucratic overhead that can delay patient access to beneficial technology.

For medical device manufacturers, the strategic implication is clear: understand both systems deeply, plan your regulatory pathway based on your target markets, and recognize that CE Mark and FDA clearance are complementary - not mutually exclusive - pillars of global market access.

• Reinstein, D.Z. & Kanellopoulos, A.J. "CE Mark Versus FDA Approval: Which System Has It Right?" Cataract & Refractive Surgery Today Europe, February 2015.
• EU Medical Device Regulation (EU) 2017/745 (MDR)
• FDA Premarket Notification (510(k)) Overview
• FDA Medical Device Classification (Class I/II/III)
• BSI - Gain Market Access in Europe with CE Marking

This article is for informational purposes and does not constitute legal or regulatory advice. Always consult with qualified compliance and legal professionals for your specific market requirements.